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Pseudomonas cepacia (PC) is a plant pathogen with 
multiple antibiotic resistance that has been the cause 
of nosocomial infections in debilitated patients, and 
has recently become a significant colonizer of the 
respiratory tracts of patients with cystic fibrosis 
(CF). One hundred and nineteen colonized patients 
with CF and their non-colonized sex and age-matched 
controls were studied to determine mortality in the 
first and second years following acquisition of PC, 
and those colonized patients who died in the first 
year were compared to those who survived to determine 
differences in pre-colonization clinical status. The 
FEV1 and RV/TLC data of 33 matched pairs were studied 
from 3 years before colonization with PC through 2 
years following colonization to determine differences 
in the decline of pulmonary function. Mortality of 
colonized patients was higher than that of controls in 
the first year (chi-square <.005), and those who died 
in the first year had worse pulmonary function one 
year prior to colonization (p=.QGl). Colonized survi¬ 
vors had a significantly lower FEVl than their con¬ 
trols over the 5 year period, with no difference in 
the rate of decline. 
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INTRODUCTION 1 . 
Cystic Fibrosis is a genetically acquired disease 
in which progressive pulmonary infection and destruc¬ 
tion is a primary clinical manifestation. While 
Staphylococcus aureus was the most common respiratory 
pathogen in patients with cystic fibrosis prior to the 
availability of antibiotics (1,2,59),Pseudomonas aeru¬ 
ginosa is currently the most common organism found in 
their sputum (56,96). Pseudomonas cepacia is an orga¬ 
nism first thought to be a pathogen only in plants, 
but which has since been described as a nosocomial 
cause of wound infections, urinary tract infections, 
bacteremia and pneumonia in humans (2,20,27,30,41,60, 
69,70,71,78,82,84,86,88,95). It has recently become a 
more common pathogen in patients with cystic fibrosis, 
and often is resistant to many antibiotics (3,4,8,19, 
24,27,31,45,49,62,64,67,81,84,87,93), making it a dif¬ 
ficult organism to treat. Its effect on the course of 
patients with cystic fibrosis is unclear, although 
some studies suggest that many patients follow a 
rapidly fatal course after acquisition of the organism 
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(10,40,91). This study was undertaken to better 
define the effect of Pseudomonas cepacia has on 
the course of patients with cystic fibrosis. 
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2. REVIEW OF THE LITERATURE 
PULMONARY BACTERIOLOGY OF CYSTIC FIBROSIS 
Cystic Fibrosis of the Pancreas is defined, in 
the 24th edition of Stedman's Medical Dictionary, as 
"a congenital metabolic disorder, inherited as an 
(autosomal) recessive trait, in which secretions of 
exocrine glands are abnormal; excessively viscid mucus 
causes obstruction of passageways (including pancre¬ 
atic and bile ducts, intestines, and bronchi) and the 
sodium and chloride content of sweat are increased 
throughout the patient's life; symptoms usually appear 
in childhood and include meconium ileus, poor growth 
despite good appetite, foul bulky stools, chronic 
cough, recurrent pneumonia, emphysema, clubbing of the 
fingers, and salt depletion in hot weather; the under¬ 
lying metabolic defect is unknown and survival beyond 
childhood is uncommon" (85). The pulmonary disease 
in Cystic Fibrosis (CF) remains the main cause of 
morbidity and mortality in affected patients (88). 
The first pathogen associated with CF lung 
disease was Staphylococcus aureus (SA), originally 
described in the first paper written on the subject by 
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Andersen in 1939 (1). While this association has been 
repeatedly demonstrated, the reason for the organism's 
predilection for the lung of patients with CF is not 
known. It has been proposed that the character of the 
pulmonary secretions in CF favor the proliferation of 
this organism, with one study reporting that increased 
p-hydroxyphenylacetic acid concentration in respira¬ 
tory secretions promoted the growth of SA (55). 
It has also been proposed that Protein A, a consti¬ 
tuent of the cell wall of SA, contributes to the 
organism's prevalence in the lung of patients with CF 
by binding to the Fc portion of immunoglobulins and 
inhibiting phagocytosis (34). Protein A has also been 
found to adsorb to precipitating antibodies to Pseudo¬ 
monas aeruginosa (PA) in patients with CF, making it a 
possible mechanism of synergism between the two 
organisms (32). 
The role of SA in the initiation of pulmonary 
damage in CF patients has also been debated in the 
literature. Lawson, in 1969, stated that it was the 
SA itself that damaged the lung, and that invasion by 
PA could only occur after this damage has been done 
(50). This hypothesis has since been refuted, most 
notably by May et al. in 1972, who found PA to be the 
most common pathogen isolated from the sputum of their 
6 to 10 year old patients with CF, with precipitating 
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antibodies against PA being more common than those 
against SA in the 0 to 10 year olds, suggesting that 
SA is not always the initial pathogen and that 
patients with CF are inherently susceptible to bron¬ 
chial infection from birth (56). 
S. aureus continued to be the primary pathogen in 
CF until the mid-1960s, although the incidence of PA 
was increasing (59). Nelson's Textbook of Pediatrics 
in 1964 stated that PA colonization was becoming more 
frequent due to the use of antibiotics in treating SA 
infection (76). This was supported by the finding, in 
1961, that 50% of CF patients hospitalized at St. 
Christopher's Hospital for Children who had received 
antibiotics had admission sputum or throat cultures 
positive for PA, while only 13% of those who had not 
been previously treated with antimicrobial drugs 
carried the organism (38). 
Despite the increased incidence of PA infec¬ 
tion, however, it was felt, as stated in a 1967 review 
article in the New England Journa1 of Medicine by 
d 'Sant 'Agnese et al., that PA was not of major signi¬ 
ficance in the pathogenesis of pulmonary destruction 
in CF, an argument supported by the fact that the 
clinical course and pathologic findings at autopsy had 
remained essentially constant since the first descrip¬ 




By 1976, however, PA was clearly the predominant 
organism infecting the lungs of patients with CF, and 
was increasingly found to be the initial pathogen 
(97). This was seen in a 1972 study which also demon¬ 
strated a decrease in the isolation of SA in all age 
groups, including babies who had not received any 
antibiotics in the past, calling into question the 
idea that the decreased isolation of SA was caused by 
increased use of these drugs. They proposed that this 
change in rates of colonization by PA and SA reflected 
a change in the flora of the hospital environment, 
indirectly implicating antibiotics (59). A later 
study in which the fifty percent of patients who had 
one or no hospitalizations remained free of PA also 
implicated the hospital environment in causing acqui¬ 
sition of PA infection (49). 
While the serotypes of SA that infect patients 
with CF are not unique to that disease (89), a large 
percentage of the PA found in these patients have a 
characteristic mucoid morphology which is not often 
found in other patients (77). A study done at the 
National Institutes of Health in 1975 reported that 
60% of PA strains from CF patients were mucoid (98), 
while a later study done in 1979 found the incidence 
of mucoid PA to be 78% in patients with CF, as 
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compared to 2% in non-CF patients infected with PA. 
The authors did not find the same prevalence of mucoid 
PA in patients with other chronic pulmonary diseases, 
and the appearance of these bacteria in the sputum of 
CF patients often preceded treatment with antibiotics, 
suggesting that the CF lung itself is more suitable to 
mucoid PA and that selection of these organisms by 
antibiotic use did not play a major role (68). 
Chronic colonization of patients with CF with 
mucoid strains of PA was associated with a signifi¬ 
cantly higher number of anti-PA precipitating anti¬ 
bodies than colonization with non-mucoid strains in a 
study that postulated that mucoid substance is a viru¬ 
lence factor which inhibits antibody-mediated killing 
of organisms (89). Another group used the high inci¬ 
dence of infection with mucoid PA at the time of death 
in their CF patients, and a decreasing prevalence of 
these organisms in their older patients, to support 
the idea that mucoid PA is quite virulent, causing 
patients who harbor it to die at a young age (97). 
The predilection of mucoid strains of PA for the 
lungs of patients with CF seems to be related to the 
interaction of the mucoid substance and the host's 
immune system. In one study, the slime from mucoid PA 
was added ini vitro to polymorphonuclear leukocytes 
along with either Eh_ coli, PA or SA. They found that 
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phagocytosis of all three organisms was inhibited, 
with the most inhibition occurring in the phagocytosis 
of PA (79). Another study showed that a preparation 
of Pseudomonas capsular polysaccharide increased the 
virulence of PA in mice, as well as the virulence of 
SA and coli (18). 
Other Pseudomonas toxins may also be responsible 
for damage to pulmonary tissue; Exotoxin A and pro¬ 
teases of PA have been shown to cause exfoliation, 
disorganization, and inhibition of protein synthesis 
and ciliary activity in hamster tracheal explants (5). 
Also, mucoid PA forms microcolonies enveloped in a 
fibrous matrix of glucuronic and mannuronic acids 
(48), and can physically clog small airways and impair 
mucociliary clearance (53). 
Interestingly, although E_^ coli is not a 
common pathogen in CF, it was found at Boston Chil¬ 
dren's Hospital in 1981 that 11.8% of the 68 patients 
with CF that had respiratory tract colonization with 
that organism harbored mucoid strains, as compared to 
0 of 89 patients without CF who had sputum cultures 
positive for E^ coli (52). The mucoid substance was 
found to be distinct from that of PA, yet its exis¬ 
tence suggests that it too imports an advantage to the 
organisms able to make it. 
Hemophilus influenza (HI) has also been reported 
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to be a common pathogen in CF pulmonary disease, even 
though its presence may be overlooked due to the rapid 
growth of other organisms in sputum from patients with 
CF and its fastidious nutritional requirements in 
vitro (89). In Denmark in 1976 HI was seen as a 
predominant colonizer of CF patients, and 38% of the 
CF population was found to have a single biotype 
present in only 11% of normal children (35). HI, 
like PA, is found more commonly in more severely ill 
patients, but its presence is not chronic like that of 
PA, due to its sensitivity to antibiotics. For this 
reason, infection with this organism is intermittent 
and recurrent (34). 
Non-fermentative gram negative rods other than PA 
were first studied in patients with CF at Yale-New 
Haven Hospital in 1982. Twenty of 170 CF clinic 
patients were found to have at least one strain, and 8 
had more than one, at least once during the 4 year 
period of study. The most common was Acinetobacter, 
appearing in 10 cultures, followed by 7 with P.putida- 
florescens, 4 with P. maltophi1ia, 4 with unidentified 
pseudomonads, 2 with P. cepacia, and one each of 
Bordetella bronchiseptica, Flavobacterium II-B and 
Achromobacter xylosoxidans. The authors did not pro¬ 
pose a specific clinical role for these species, but 
did suggest that accurate identification of gram 
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negative organisms would allow increased recognition 
of non-PA species, and that this, along with the usual 
resistance of many of them to common antibiotics, 
would have to be taken into account in designing 
therapy for those patients colonized with them (6). 
Other bacteria have also been found in the pulmo¬ 
nary secretions of patients with CF, as well as occa¬ 
sional fungi (89). A 1980 paper by Boxerbaum et al. 
describes the case of a 17 year old girl with a posi¬ 
tive PPD and evidence of infection with Mycobacterium 
chelonei♦ He also identified 7 other patients with 
CF, aged 21 to 33 years, with rapidly growing mycobac¬ 
teria in their sputa (11). Legionella pneumophila 
antibodies were found in 29.4% of 109 CF patients 
studied by Katz et al. in 1982, as compared to 11.5% 
of 26 patients with chronic suppurative bronchitis of 
childhood and 1.7% of 178 age matched controls without 
pulmonary disease. The patients with high titers of 
anti-Legionella antibodies were in worse clinical 
condition than the others, and the authors concluded 
that the organism was an opportunistic pathogen in 
already devastated lung tissue (94). Mention is also 
made in the literature of CF patients harboring other 
organisms, often gram negative, but they are also 
considered to be secondary invaders, and not specific 
to CF lung disease. 
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The influence of less commonly encountered non- 
bacterial pathogens on the course of CF pulmonary 
disease is also unclear, although it has been postu¬ 
lated that there may be synergism between some of 
these agents and PA. One study described 116 patients 
with CF who were followed over 8 months to determine 
the frequency of exacerbations of pulmonary disease 
and their cause. Twenty percent were attributed to 
non-bacterial respiratory tract pathogens; 9% to res¬ 
piratory syncitial viruses (RSV), 5% to parainfluenza 
viruses, 3.6% to influenza viruses, 2.4% to adeno¬ 
viruses, 0.6% to Mycoplasma, and 0.6% to Chlamydia. 
RSV infections were more common in patients who devel¬ 
oped chronic PA infection during the study period, and 
were frequently associated with a rise in PA antibo¬ 
dies in patients who previously harbored these organ¬ 
isms, suggesting a synergistic pathogenicity between 
the two (66). It is possible that other examples of 
synergism between respiratory pathogens occur in the 




Pseudomonas cepacia (PC) was first described in 
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1950 as a plant pathogen, causing sour skin in onions 
(13). It was previously known as multivorans or P. 
kingii, which had previously been called "eugonic 
oxidizer group number one" (EO-1) (24). Later it was 
noted to be a human pathogen, associated with urinary 
tract infections, wound infections, pneumonia, and 
bacteremia in a variety of patients, and later with 
CF. Often colonization did not lead to symptomatic 
disease; when clinical illness did occur, the patients 
tended to be debilitated or have another cause of 
impaired host defenses. 
In many reported cases the source of the organism 
was found in the hospital environment, often in con¬ 
taminated detergents and disinfectants. In 1958, 40 
patients who were exposed to needles and catheters 
stored in cationic surface active detergent which 
harbored PC developed bacteremia (69). PC also grows 
well in chlorhexidine and has caused urinary tract 
infections in patients where this antiseptic was used 
prior to cystoscopy (60), post-operative wound infec¬ 
tions in patients exposed to contaminated 10:1 
cetrimide-chlorhexidine solutions (7), and bacteremia 
when chlorhexidine was used to clean intravenous infu¬ 
sion sites (84). In the latter study, many gram 
negative organisms were isolated from the infected 
solution, but only PC was found in cultures from 
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patients. This was interpreted as evidence for selec¬ 
tion of PC in patients receiving antibiotic therapy. 
PC has also been shown to grow well in benzylko- 
nium chloride solution, where it has been linked to 
contamination of intravenous and arterial blood 
pressure monitoring equipment (95), intravenous infu¬ 
sion lines (20), and skin (41). In 1970 benzylko- 
nium chloride in commercially packaged urinary cathe¬ 
ter kits was found to contain PC, and caused bactiuria 
in 13 patients, two of whom developed symptoms of 
urinary tract infection (30). 
Forty-one patients in one hospital became infec¬ 
ted with PC in 1972, 26 with urinary tract infections, 
one with bacteremia, 12 with respiratory tract infec¬ 
tions, and 10 with wound infections, and eventually 
contaminated benzyl ammonium chloride was identified. 
All of these patients were debilitated, 69% had been 
on antibiotics, and 37 of them had prior manipula¬ 
tion of the infected site. The authors concluded that 
hospitalized persons with serious underlying pathology 
were essentially the only population at risk for symp¬ 
tomatic PC infection (19). 
Topical anesthetics have also been responsible 
for acquisition of PC by hospital inpatients and out¬ 
patients. Twenty-two patients seen in one ENT clinic 
were found to have respiratory washings positive for 
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PC in a one year period. The organisms were traced to 
topical tetracaine and cocaine anesthetics used in 
this clinic, and ultimately to deionized water used by 
the pharmacy to make these compounds. No clinical 
disease was noted despite large inocula (78). Bron¬ 
chial washing cultures positive for PC have also been 
linked to viscous lidocaine used during bronchoscopy 
(71) . 
In another study, fifty-six patients at a Veter¬ 
ans Administration Hospital were reported to have 
cultures positive for PC. A very low rate of clinical 
infection was seen in those whose exposure to the 
organism was traced to contaminated cocaine used in 
the ENT clinic or lidocaine used in bronchoscopy. For 
26 patients, however, no source of PC was found, and 
the rate of infection was high, including six cases of 
bacteremia and two cases of pneumonia. Twenty-three 
of those 26 patients had been intubated during their 
hospitalization, suggesting a possible mode of entry 
for the organism. The authors felt that the serious 
infections in these patients were related to their 
overall clinical status, which was worse than that of 
the others, as well as the increased use of intravas¬ 
cular devices in this group (54). 
While the above studies suggest that PC is a 
relatively benign organism in healthy subjects. 
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several studies have documented severe disease caused 
by PC in previously ill patients. In 1975, for 
example, a twenty-one year old patient with chronic 
granulomatous disease (CGD) with impaired phagocyte 
function was reported to have recurrent pneumonitis 
caused by PC. This patient, while exhibiting a more 
benign course than the usual person with CGD, does 
demonstrate that PC pulmonary infection can be re¬ 
current, and suggests that chronic immunocompromise 
may be responsible (16,17). 
The role of PC infection in CGD was also ad¬ 
dressed in a report of three patients, one of whom had 
pleural space cultures positive for PC, another with a 
lymph node infected with the organism, and a third 
with abscess cultures positive for PC. The authors 
felt that the chronic antibiotic therapy to which 
patients with CGD are exposed played a significant 
role in allowing this colonization and infection (9). 
The clear association of clinically significant 
PC infection with poor underlying clinical status is 
emphasized by a 1982 Israeli study which describes 
non-pathogenic colonization of patients exposed to 
chlorhexidine that was diluted with contaminated de¬ 
ionized water. Only two patients, both of whom were 
immunocompromised, developed fulminant sepsis; both 
had growth of PC in urine and blood cultures (82). 
-15- 

In another study, which describes PC bacteremia 
following open heart surgery due to contaminated 
pressure transducers, the authors again note that 
possible differences in host resistance, as determined 
by absence of the expected leukocytosis in the 24 
hours following extracorporeal circulation, determined 
which of their patients developed clinical infection. 
While all patients studied had comparable pre-opera¬ 
tive WBC's, infected patients were found to have sig¬ 
nificantly lower mean WBC's in the first day after 
surgery (95). 
Other PC infections reported include macerated 
keratotic foot lesions in British troops training in 
swamps where the organism is endemic (88), a lung 
abscess in a diabetic patient which was linked to 
contaminated water in an ultrasonic nebulizer (70), 
bacteremia in 10 patients at the University of Mary¬ 
land Hospital who were treated with contaminated 25% 
normal serum albumin (86), and pneumonia in a child 
following surgical repair of Tetrology of Fallot (94). 
Antibiotic therapy 
The prognostic implications of infection with PC 
in immunocompromised or debilitated hosts are serious, 
due to the resistance of this organism to most avail¬ 
able antibiotics. In all of the studies sited above, 
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PC was difficult to treat, almost always exhibiting 
resistance to ampicillin, tetracycline, streptomycin, 
colistin, cephalothin, and cefaloridine, and often 
resisting eradication with gentamicin, tobramycin, 
carbenici11in, ticarcillin, and other agents used to 
treat infections with gram negative organisms. 
Antibiotic resistance in PC is thought to be 
caused by the presence of resistance plasmids. These 
intercellular elements were isolated from 11 of 48 
strains of PC in one study, though their function was 
not studied. The rate of plasmid occurrence may have 
been higher than this, but the presence of nucleases 
in the electrophoresis preparation may have broken 
down these plasmids before they were recovered (58). 
Antibiotic resistance was again shown to be due, at 
least in part, to resistance plasmids when they were 
taken from PC and used to transform coli HB101. 
The resultant transformed coli exhibited new ampi¬ 
cillin and tetracycline resistance similar to that of 
PC (96). 
Gentamicin is an example of an antibiotic that 
was developed for use in serious gram negative bacil¬ 
lary infections which is almost never active against 
PC. It was tested following its approval for clinical 
use by the FDA, and while PA was found to be 51% 
sensitive at a drug concentration of 1 ug/ml, 97% 
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sensitive at 5 ug/ml, and 100% sensitive at 20 ug/ml, 
PC was insensitive at each of these concentrations 
(93). At that time PC was not a commonly found 
organism, and only two strains were tested, however 
gentamicin resistance of PC has been reported 
repeatedly (9,19,67,87), with occasional reports of 
variable sensitivity (84). Only two investigators 
have found PC isolates to be sensitive to gentamicin, 
and in both at least half of the strains tested were 
resistant (6,62) . 
The most useful antibiotics in the treatment of 
PC infection since this organism began appearing in 
the medical literature have been chloramphenicol and 
trimethoprim/sufamethoxazole (TMP/SXZ). Throughout 
the 1970 's, in fact, these two compounds were the only 
consistently effective antibiotics reported. I_n vitro 
sensitivity to chloramphenicol has been described 
repeatedly (8,9,19,24,62,81,84,94), but in. vivo effec¬ 
tiveness has been variable, especially in patients 
with serious underlying illness. For example, a hero¬ 
in addict with persistent PC tricuspid endocarditis 
who was treated with high dose chloramphenicol to 
which his PC was sensitive _in vitro, but in whom 
relapse was not prevented was reported in 1973 (73). 
In 1977, patients with CF whose PC was reported to be 
sensitive to chloramphenicol in vitro, showed good 
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clinical response to treatment with the drug, but the 
organism was only eradicated in a few cases (49). 
Sensitivity of PC to chloramphenicol has been 
decreasing with time. According to one group, in 1977 
only "a few" of the 402 respiratory tract cultures 
from patients with CF at their institution that grew 
PC were sensitive to chloramphenicol (49). Half of 
the eleven gentamicin and tobramycin resistant strains 
of PC and P. maltophilia isolated from patients with 
CF at another hospital were resistant to chlorampheni¬ 
col in 1979 (8), more than half of the 13 strains 
isolated from patients with CF at another institution 
between 1/79 and 12/83 were resistant (87), and 
another group reported that few strains of PC remained 
sensitive to this drug in 1986 (27). 
In many studies TMP/SXZ was the only compound 
found to be effective in. vitro against'PC (8,75,84), 
but more recent reports show a decline in the useful¬ 
ness of this agent as well (27,87). Resistance to 
sulfonamide alone is occasionally reported in the 
literature (84,62), but no reports appeared until the 
early 1980 's in which the combination was found to be 
ineffective in inhibiting PC in. vitro. In fact, the 
combination of TMP and SXZ has often proved more 
effective than either of the two drugs alone. In one 
study, PC was found to be very sensitive to TMP alone, 
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but the addition of SXZ decreased the occurrence of 
TMP resistance and potentiated the effects of TMP on 
organisms that were previously resistant (63). Syner¬ 
gism has also been shown between TMP/SXZ and colistin, 
an agent which is never effective alone (64). 
Interestingly, in 1973 synergism was also de¬ 
scribed between TMP and polymyxin B, another agent 
found repeatedly to be ineffective against PC 
(19,67,94), and this synergism was enhanced by sul¬ 
fonamide, leading the authors to suggest that combina¬ 
tion therapy with these agents may be beneficial (73). 
Other antibiotics have sporadically shown limited 
in vitro activity against PC, but agents such as 
novobiocin (24), nalidixic acid (19), kanamycin 
(49.62.84.87) , neomycin (9,62), carbenici11in 
(6.9.67.84.87) , cefoperazone (81), tobramycin (6,87) 
and moxalactam (81,87) have not been consistently 
active in vitro and have been rarely employed i_n vivo. 
The resistance of PC to penicillins and cephalo¬ 
sporins is related to the presence of an inducible 
beta-lactamase which hydrolyzes many of these com¬ 
pounds (31). It was hoped, however, that third 
generation cephalosporins would not be affected by 
this enzyme. In 1983, a study was done which con¬ 
sidered the efficacy of ceftazidime in treating CF 
patients with PC infection, and although they found 
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most strains at their hospital to be inhibited by 4 
mg/1 or less of the drug in vitro, one third of the 
treatment courses were considered failures in the 
face of deteriorating clinical status, and only one of 
19 patients had significant reduction of colony counts 
in his/her sputum. These failures were thought to 
reflect either failure of penetration of the sputum by 
the drug, failure of delivery of sufficient amounts of 
drug to severely ectatic lung, overwhelming inocula of 
PC in bronchial secretions, impaired phagocyte 
function in the CF lung, antibiotic interference by 
pus, or some combination of these factors (26). 
In 1985 the in vitro activity of cefpiramide, 
ceftazidime, piperacillin, ticarcillin, and aztreonam, 
all beta-lactam anti-pseudomona1 agents, were compared 
against PA and PC in children with CF. All were 
tobramycin and amikacin resistant. They found cef¬ 
tazidime to be the most effective in. vitro agent, 
inhibiting 90% of the isolates at a concentration of 8 
mg/1. Fifty percent were sensitive to 32 mg/1 or less 
of cefpiramide, fifty percent were susceptible to the 
same concentration of aztreonam, and ticarcillin was 
the least effective agent tested (4). This apparent 
activity of ceftazidime against PC, while encouraging, 
must be viewed in light of the earlier _in vivo failure 
of the drug. 
-21- 

In another recent study, the effects of aztreo- 
nam, piperacillin, and ticarcillin, alone and in 
combination with amikacin, were tested against 
amikacin resistant PA and PC isolated from the sputum 
of patients with CF. It was reported that 86.3% of 
the 22 strains of PC were sensitive to 16 ug or less 
of piperacillin, and 100% were susceptible to the 
combination of this drug with amikacin. Twenty-two 
percent were sensitive to aztreonam alone and 81.8% 
when amikacin was added, and none of the PC was sensi¬ 
tive to ticarcillin, with or without the second drug. 
The authors suggested that while in vivo data had not 
been collected, the in vitro results made combination 
therapy with these drugs an attractive alternative 
(3) . 
Ciprofloxacin, a new oral oxyqui.noline derivative 
with significant anti-pseudomona1 activity, has also 
been studied, along with norfloxacin, mezlocillin, 
azlocillin, aztreonam, imipinem, ceftazidime, and 
cefsulodin for in vitro activity against sputum PA and 
PC isolates from patients with CF. With inocula of 
one million colony-forming units per ml, ciprofloxa¬ 
cin, norfloxacin, and ceftazidime were inhibitory, 
while the others were not. At larger inoculum sizes 
there was decreased inhibitory activity of norfloxacin 
and ceftazidime, but not of ciprofloxacin. The 
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authors suggest that oral ciprofloxacin may be a use¬ 
ful agent for treating pseudomonal pulmonary exacerba¬ 
tions, both by PA and PC, in CF patients, its oral 
form making outpatient therapy possible (4). 
PSEUDOMONAS CEPACIA IN CYSTIC FIBROSIS 
The first report of PC isolation from a 
patient with CF appeared in the literature in 1972, in 
a study by Ederer et al. of the incidence of PC infec¬ 
tion and colonization of patients at the University of 
Minnesota Hospital. In their 2 year study, from Jan¬ 
uary, 1968 through December, 1969, PC was isolated 115 
times from 41 patients, each of whom had a major 
debilitating condition, with cancer being the most 
common diagnosis. Of the 41, one patient suffered 
from CF, but no details of this individual's course 
are given, and it is unclear whether or not this 
patient's colonization was felt to be clinically sig¬ 
nificant (19). 
In 1977 an abstract was published in Pediatric 
Resident reporting 402 PC isolates out of 6364 
respiratory tract cultures obtained between July, 1973 
and December, 1976 from CF patients at St. Christo¬ 
pher's Hospital for Children. This report first 
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raised the question of the significance of that organ¬ 
ism specifically in patients with CF (49). 
The first case report appeared in 1980, when 
Rosenstein and Hall described a 17 year old girl who 
was admitted for the first time to the hospital, whose 
CF had followed a slowly progressive course until that 
time. No pseudomonads had been found in her sputum 
cultures for the four years prior to admission. She 
had been treated continuously with cloxacillin and 
tetracycline for the two years prior to admission, and 
had not been treated with home nebulizers. Her clini¬ 
cal course was rocky, and she required intubation, but 
her sputum PC eventually cleared after treatment with 
multiple antibiotics (75). Since that report, PC has 
become the subject of concern in many CF centers where 
its prevalence has been increasing. 
Many studies have been done which attempt to 
define the incidence and prevalence of infection with 
PC in patients with CF. In 1977, 6.3% of sputum 
cultures from patients with CF at St. Christopher's 
Hospital in Philadelphia grew PC. Fifty-four patients 
had positive cultures, their ages ranging from 2.5 to 
22 years. Fifty-nine percent of those colonized were 
female and 41% male; 3.7% had mild underlying lung 
disease, 27.5% had moderate disease, and in 68.5% 
advanced pulmonary involvement was noted. Twenty- 
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eight percent of the colonized females died, as com¬ 
pared to 22.7% of the males. No data was given which 
compared these numbers to the mortality rate of 
patients with CF who were not colonized with PC (49). 
In contrast, at Yale-New Haven Hospital between 
1975 and 1979 only two of 170 patients were found to 
have PC growth in their sputum. Although the patients 
carrying PC were not analyzed separately, the authors 
noted that 75% of the 20 patients found to harbor any 
species of non-fermentative gram negative rod other 
than PA were in good to excellent clinical condition 
when the organisms were first isolated. During their 
period of study only one patient died; his/her in¬ 
fecting organism was not noted (6). 
More recently it was reported that the prevalence 
of PC colonization among patients with CF at Rainbow 
Babies' and Children's Hospital in Cleveland (RB&C) 
had increased from 7 to 15% between 1978 and 1983. 
The mean age of acquisition was 18.1 plus or minus 4.9 
years for males, and 18.8 plus or minus 4.9 years for 
females. In the first 3 years of this study, 60% of 
patients who acquired PC were in poor condition at the 
time of colonization, while in the 5th year only 18% 
were in poor condition, indicating an increasing trend 
not only in the prevalence of overall colonization, 
but in the prevalence among patients in better 
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clinical condition. Also, there was a trend toward 
younger ages of colonization; between 7/81 and 6/83 
eight patients less than 12 years of age were colo¬ 
nized, while prior to 1981 only 2 in that age group 
had positive cultures (91). 
In a paper by Corey et al., an increasing preva¬ 
lence of PC colonization among the patients with CF at 
the Hospital for Sick Children in Toronto was also 
noted. Between 1970 and 1977, 4-5% of their patients 
younger than ten years of age, and 12-15% of those 
older than ten, had positive sputum cultures; in 1981 
9% of the younger children and 21% of the older group 
were colonized. The overall prevalence increased 
during this time period from 9.6 to 18.1%. In that 
institution more girls were affected than boys, and 
the mean age of acquisition was 13.7 plus or minus 7.2 
years (14). 
A 1985 paper from St. Christopher's showed a 
different trend at that institution. Between 1/79 and 
12/83 the prevalence of PC colonization among patients 
with CF decreased from 20.4% to 12.2%. The authors 
suggest that this decreasing trend may be explained by 
a greater rate of mortality in those patients affected 
than the rate of colonization among those not 
affected. In that study the mean age of first isola¬ 
tion of PC was 12.1 years. These studies seem to 
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define the trend as being toward greater rates of 
colonization by PC of patients with CF and PC, with an 
increasing number of younger and less severely debili¬ 
tated patients becoming affected (87). 
Other possible risk factors have also been ad¬ 
dressed in the literature, and because most earlier 
reports of infection with PC were traced to contami¬ 
nated hospital equipment, investigators have been 
concerned that hospitalization would be a significant 
risk factor for PC acquisition in patients with CF. In 
the 1977 abstract from St. Christopher's cited above, 
the authors state that PC had been cultured from the 
sputum of patients with CF who had never been hospi¬ 
talized and who rarely used aerosol therapy (49). In 
a later study at that institution, no PC was identi¬ 
fied in cultures of water, respiratory therapy equip¬ 
ment, or medicine vials, but despite these negative 
cultures an association between acquisition of PC and 
frequent visits to the outpatient clinic of that hos¬ 
pital was noted, raising the question of an obscure 
nosocomial source (87). 
At (RB&C), Thomassen et al. determined that 56% 
of 85 colonized patients had their first positive 
culture during or immediately following hospitaliza¬ 
tion (91). Although multiple cultures were done on 
hospital equipment, water and other environmental 
-27- 

objects and personnel, the source of the organism was 
never identified (92). At the Hospital for Sick 
Children, however, growth of PC from spirometers and 
other equipment from their pulmonary function labora¬ 
tory was reported by Isles et al., defining the source 
of at least some of the PC found in their patients 
(40) . 
Another risk factor for PC colonization seems to 
be the presence in the same home of a sibling with CF 
who is colonized with PC. In 1985, Tablan et al. 
found that colonization with PC was significantly more 
likely in patients who had such a sibling, as well as 
in those with more severe underlying pulmonary disease 
and in those who had received aminoglycoside antibi¬ 
otics in the three months prior to the first positive 
culture (87). At RB&C, Thomassen et al. followed 16 
pairs of siblings with CF in which at least one was 
colonized with PC, and found that in 6 pairs the other 
child was also chronically colonized and in 3 pairs 
the second child was colonized intermittently. This 
was a marked increase in incidence of PC colonization 
from about 17% of the overall CF population of that 
institution to 37.5% in those with affected siblings 
(91 ) . 
The apparently increased incidence of PC coloni¬ 
zation among siblings suggests that person-to-person 
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transmission might occur. In Danish CF clinics in 
1982, patients were found to be colonized with predo¬ 
minantly one strain of PC, which could be explained by 
transmission from patient to patient or by a common 
source of exposure, perhaps located in the clinic 
itself (72). It is known that transmission of PA 
requires prolonged intimate contact, as siblings might 
have, but only one study addressing that question in 
PC colonization has been done. In this study, Honicky 
et al. did not find andy increased incidence of PC 
colonization at the end of one week at a CF camp (37). 
The short duration of exposure and lack of subsequent 
follow-up make conclusions difficult to draw. 
One study which does support the idea of person- 
to-person spread of PC is from RB&C, where the 
patients with CF who are colonized by PC are physi¬ 
cally separated from those without the organism in the 
hospital, and even in separate summer camps. They 
have found the overall incidence of PC colonization to 
have decreased with these measures, from 8.2% in 1983 
to 1.7% in 1984 (97). 
One other risk factor that is suggested in the 
literature is that of female sex. Boxerbaum et al. 
propose that post-pubertal females have an increased 
risk of colonization, in an abstract which reports 
four such patients with fulminant PC bacteremia (10). 
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Tablan, however, found no such correlation in an epi¬ 
demiologic investigation done in 1985, and the matter 
remains unresolved (87). 
While questions of true incidence, risk factors 
and transmission are all important, the most basic 
question about infection with PC in patients with CF 
is what, if any, effect does it have on the clinical 
course of the patients. Isles et al. describe three 
different clinical courses that they found in these 
patients. Those in the first group acquire PC with 
little change in the progression of their disease, in 
the second they continue on an already downhill 
course, and in the third a fulminant downward course 
developed, leading to sepsis and death (40). The first 
case report of a CF patient with PC, in fact, was that 
of a seventeen year old girl who had been in previous¬ 
ly good condition who acquired PC and followed this 
third pattern, developing sepsis with respiratory 
failure, right ventricular failure, SIADH, hypergly¬ 
cemia, and pneumothorax (75). 
Boxerbaum describes four more cases of female CF 
patients with mild disease whose becoming colonized 
with PC was followed by a rapidly fatal course. Three 
of these patients lived less than three weeks follow¬ 
ing colonization. Their courses were very different 
from the more slowly progressive decline associated 
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with PA infection, and were marked by spiking fevers, 
leukocytosis, and bacteremia (10). 
The trend followed by patients with CF who were 
colonized with PC at RB&C, reported in 1984, was that 
of a distinctly faster deterioration in clinical sta¬ 
tus than non-colonized patients, and the prognosis 
seemed to be worse for females. Fifty-one percent of 
females had a decline in status in the year following 
colonization, regardless of their initial condition, 
while only 30% of the males followed this trend. Of 
those patients initially in good clinical condition, 
64% of the females had a decline in status concurrent 
with acquisition of PC, while only 6% of the males 
did. The proportion of colonized patients following a 
downhill course after acquiring PC was seen to be 
increasing; in the first year of the study 9% of all 
CF deaths were associated with PC while a full 55% of 
deaths in the fifth year fell into this category. The 
largest increase was seen in the group of patients 
that followed a rapid and fulminant course (91). 
In contrast, at the Hospital for Sick Children, 
Isles et al. reported that while the absolute pulmo¬ 
nary function parameters of their CF patients with 
either PC alone or PC and PA in their sputum were 
worse than those of patients with PA alone, the 
slope of decline between the two groups did not 
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significantly differ. However, among girls with PC, 
mortality was 50% over one year, while girls with PA 
had a mortality rate of 6%. Poor prognostic indica¬ 
tors in female patients with PC were the presence of 
fever and leukocytosis. Sixty-two percent of girls 
admitted with PC and fever died, and of those who died 
the mean WBC on admission was 25,500, while it was 
14,000 in those who lived. Similar studies were not 
reported for boys. Among all patients with CF admit¬ 
ted to the hospital with PA, only 18% had fever, while 
44% of those with PC were febrile on admission. Also 
in that paper 7 cases of mild to moderately ill 
patients with CF who developed fulminant, rapidly 
progressive pulmonary infection with PC, similar to 
those reported by Boxerbaum, were described. This 
study suggests that patients admitted to the hospital 
with PC pulmonary infection, fever, and leukocytosis 
are at greater risk of death, and that this risk seems 
to be increased in females (40). 
At St. Christopher's it was found that hospital¬ 
ized patients who were colonized with PC had an 
increase in the mean proportion of time that they 
spent in the hospital for pulmonary symptoms from 9% 
in the year prior to colonization to 21.3% in the year 
following colonization. In controls, the proportion 
during the same time period decreased from 2.8% to 
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1.9%. For their CF patients, colonization with PC, as 
well as severity of pulmonary disease and female sex, 
were found to be independent indicators of poor prog¬ 
nosis ( 87 ) . 
The worsening clinical course reported in these 
recent studies to be associated with PC colonization 
and infection is not proven to be caused by this 
organism. It is also conceivable that deterioration 
caused by some unrelated factor allowed patients to be 
more susceptible to PC colonization. The possibility 
that PC, an organism which is difficult to treat, does 
cause such devastating deterioration, however, makes 




3 . METHODS 
Subjects were chosen from the Cystic Fibrosis 
Database of Rainbow Babies' and Children's Hospital, 
(RB&C) Cleveland, Ohio, which includes all patients 
who attend that institution's cystic fibrosis clinic. 
One hundred and forty-six patients with Pseudomonas 
cepacia colonization, as determined by three sequen¬ 
tial positive sputum cultures, were identified. The 
date of acquisition was recorded as the date of the 
first positive culture. 
One matched control was chosen from the RB&C 
database for each colonized subject. The matches were 
assigned on the basis of sex, age within six months of 
the subject, and survival at least until the time of 
the subject's acquisition of PC. Where more than one 
suitable match existed, an attempt was made to choose 
that patient who had the most pulmonary function data 
for the period from three years prior to the date of 
PC acquisition of his/her match to two years following 
the acquisition date. Matches were found for one 
hundred and nineteen of the original subjects; 
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sixty-three were males and fifty-six were females. 
Records of the pulmonary function laboratory were 
searched for each colonized subject and matched con¬ 
trol, and all values of actual forced expiratory 
volume in one second (FEV1) and residual volume to 
total lung capacity ratio (RV/TLC) for the three years 
prior to PC acquisition and two years following acqui¬ 
sition were recorded. In each uncolonized control 
subject, the date of acquisition of PC the of his/her 
corresponding colonized subject was used. Each 
patient's date of birth and height at the time of 
each test was also recorded. 
Fifty-six matched pairs in which one patient had 
less than three tests during this five year period, and 
thirty pairs in which one patient 's data did not cover 
at least the time span from one year prior to PC 
acquisition to one year post acquisition were 
identified and were excluded from the regression 
analysis performed below. The remaining 66 patients 
included twenty male and thirteen female pairs. 
From the remaining data each patient 's age at the 
time of each pulmonary function test, and the time 
between each test and the date of PC acquisition were 
calculated. 
To convert the raw FEVl values into a standard 
form, the formulae of Knudson et al. were used to 
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calculate the predicted FEV1 for each test (46). The 
actual values were then divided by the predicted 
values and multiplied by 100 to determine the percent 
of predicted FEV1 for each test. The formulae em¬ 
ployed were as follows: 
Sex Age (yrs) Expected FEVl 
Male 6-11.99 -2.8142 + 0.0348(ht in cm 
Male 12-24.99 -6.1181 + 0.0519(ht) + 
0.0636(age in yrs) 
Male >25 -6.5147 + 0.066 5(ht) - 
0.0292(age) 
Female 6-10.99 -2.7578 + 0.0336(ht) 
Female 11-19.99 -3.7622 + 0.0351(ht) + 
0.0694(age) 
Female >20 -1.8210 + 0.0332(ht) - 
0.0190(age) 
To remove some of the variation in each indivi¬ 
dual 's values, the one test with the highest percent 
of predicted FEV1 was chosen for each one month period 
within the five years chosen above for each subject. 
The RV/TLC value for that date was also included. 
Each patient's highest percent of predicted FEVl and 
lowest RV/TLC for each two month period was also 




Mortality rates were determined for the colonized 
subjects and matched controls at one year and two 
years post-acquisition of PC. The date that each 
deceased patient was last seen at RB&C was used as an 
approximate date of death. The mortality rate of the 
colonized subjects was compared to that of the con¬ 
trols, and the rate of death among the female subjects 
to that of the males using chi-square analysis. 
RISK FACTORS FOR POOR OUTCOME 
The 34 colonized subjects who died within one 
year of acquisition of PC were identified and the FEVl 
and RV/TLC values of the one test date closest to 
exactly one year prior to the date of PC acquisition 
was recorded for each. The corresponding data of each 
of their matched controls was also recorded. Thirteen 
instances in which either a colonized subject or his/ 
her control did not have any test data between .5 and 
1.5 years prior to the date of acquisition were not 
included. If two test dates were equidistant from the 
date one year prior to acquisition, that test date 
which was closer to the actual acquisition date was 
chosen. The same procedure was followed for the 85 
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colonized subjects who survived more than one year 
following acquisition and their controls, and the 
average FEV1 and RV/TLC values of the two groups were 
compared using t-test analysis to determine whether 
statistically significant differences existed between 
them. 
The age of each patient included above when he/ 
she acquired PC were also determined. The average age 
of acquisition of those patients who survived at least 
one year after acquisition of PC was compared to that 
of those who did not survive one year to determine 
whether a significant difference existed. 
PULMONARY FUNCTION 
To visualize the data for colonized subjects and 
their controls, a plot was made of the mean percentage 
of predicted FEV1 of the 33 subjects with sufficient 
data versus time since PC acquisition, for the five 
year period defined above. This was plotted on the 
same axis as the corresponding plot for the control 
patients. Values included in these plots were each 
patient's best FEV1 values for each two month interval 
beginning at 36 months prior to acquisition PC and 
ending at 24 months after acquisition, as determined 
above. Similar plots were then made for female and 
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male patients separately. 
A graph of mean RV/TLC versus time since acqui¬ 
sition of PC was also made using all 33 colonized 
subjects and was plotted on the same axis as the 
corresponding plot for controls. Values chosen were 
each patient's lowest RV/TLC reading for each two 
month period as described above. Separate plots were 
then made for females and males. 
To determine the slopes of the lines generated 
above, linear regression analysis was done using each 
patient's best test in each one month period, and the 
slopes and intercepts of the subjects' lines were 
compared to those of the controls to determine whether 
a significant difference existed. These parameters 
were also studied separately in female and male sub¬ 
jects to determine whether or not gender was related 
to the pulmonary sequelae of colonization by PC. 
To assess whether the slopes of these lines 
changed following acquisition of PC, regression analy¬ 
sis was employed separately for the portion of each 
line that fell into the time period from 36 months to 
12 months prior to the PC acquisition date and from 
the acquisition date to two years later. The period 
of one year just prior to PC acquisition was not 
included because it was felt that in that time period 
some of the patients would have already been 
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colonized, due to the impossibility of determining an 
exact date of acquisition. These slopes were then 
compared to determine whether any change had occurred. 
Comparison was also made between the slopes and inter¬ 
cepts of similar data for male and female patients. 
Because the above data included different numbers 
of tests for each patient, the graphs and regression 
data generated above were weighted toward those 
patients with more tests. To eliminate this bias, the 
slopes and intercepts of each individual 's data were 
determined by linear regression analysis. It was 
necessary to determine only one slope and intercept 
for the whole five year period for each patient, as 
there were not enough individuals with sufficient data 
to analyze the periods prior to and following acquisi¬ 
tion of PC separately. T-tests were then employed to 
determine whether significant differences exist 
between the average FEV1 and RV/TLC lines of subjects 
and controls, and between those of male and female 
subjects and their respective controls. 
Multivariate analysis of variance was then done 
to confirm the results of the t-tests in determining 
the statistical effects of gender and colonization by 
PC on the FEV1 and RV/TLC of subjects and controls. 
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4 . RESULTS 
MORTALITY 
Of the 119 subjects colonized by PC, 28.6% 
(34/119) died in the first year following its acquisi¬ 
tion. None of their 119 matched controls died in the 
same one year period, a significant difference in 
mortality (chi-square < . 005 ). 
In the second year following acquisition of PC, 
five of the remaining 85 subjects died (5.9%), while 
five of the 119 controls (4.2%) died in that year. 
This was not a statistically significant difference in 
mortality (chi-square >.05). 
In the first year following the date of acquisi¬ 
tion of PC, 25.4% (16/63) of the male subjects and 
32.1% (18/56) of the female subjects died, not a 
statistically significant difference (chi-square=.05). 
There was also no statistically significant difference 
in mortality of males and females in the second year, 
with 2.1% (1/47) of the males and 10.5% (4/38) of the 
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females dying in that period (chi-square >.05). 
RISK FACTORS FOR POOR OUTCOME 
The average percent of predicted FEV1 of the 21 
colonized patients who died within one year of PC 
acquisition was 34.0 one year prior to colonization, 
while that of the colonized patients who survived at 
least one year was 53.9, (p=.001). The mean RV/TLC 
value of the colonized patients who did not survive 
one year was 0.53 while that of the survivors was 
0.47, (p=.002). The mean age of PC acquisition of the 
survivors was 18.9 years, not significantly different 
from that of the non-survivors, which was 19.8. 
PULMONARY FUNCTION 
A plot of mean FEVl (as percent of predicted) vs. 
time for patients and controls is shown in figure 1. 
Figures 2 and 3 show the corresponding graphs for boys 
and girls respectively. Figure 4 shows mean RV/TLC 
vs. time for all patients and controls, and figures 5 
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Figure 1. Mean FEV1 as a function of time since colonization with PC 
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Figure 2. Mean FEV1 as a function of time since colonization with PC 
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Figure 3. Mean FEV1 as a function of time since colonization with PC 
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Figure 4. RV/TLC as a function of time since colonization with PC 
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Figure 5. RV/TLC as a function of time since colonization with PC 
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Figure 6. RV/TLC as a function of time since colonization with PC 
in 13 colonized female subjects and their controls. 
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The slopes and intercepts of the lines generated 
by regression analysis of the above graphs are shown 
in table 1. Significant differences were found between the 
FEV1 and RV/TLC lines generated for the colonized 
subjects and controls, with a lower intercept and more 
negative slope in the subjects' FEV1 data, and a 
higher intercept and more positive slope in their 
RV/TLC data over controls. This suggests that the 
colonized subjects had poorer pulmonary function over 
those five years than the controls, and that their 
pulmonary function declined more quickly. 
Colonized male subjects, when considered separ¬ 
ately, demonstrated a lower FEV1 intercept than their 
controls, but did not have a significantly different 
rate of decline, while they had both a higher inter¬ 
cept and faster rate of increase in their RV/TLC than 
controls. Female subjects were somewhat different in 
their response, showing both a lower intercept and 
more negative slope in FEV1 and a higher RV/TLC inter¬ 
cept with no difference in slope from their controls. 
When comparing colonized male subjects to their 
female counterparts, a significantly higher FEVl 
intercept and lower RV/TLC intercept were seen in the 
males, while the slopes of the two parameters did not 




Regression analysis of FEVl and RV/TLC data 
of 33 subjects and controls over a five year period 
FEVl S.E. RV/TLC S.E. 
COLO si -4.26101 0.76137 0.02100 0.00471 
int 43.66107 1.10397 0.48682 0.00690 
CONTROLS si -2.38264 0.85320 0.00868 0.00574 
int 58.16482 1.25967 0.42044 0.00846 
M COLO si -3.72658 0.95743 0.02310 0.00612 
int 46.23574 1.41330 0.48181 0.00902 
M CONTROLS si -2.74193 1.21641 0.00550 0.00841 
int 59.26513 1.77729 0.40918 0.01222 
F COLO si -4.89849 1.21406 0.01835 0.00730 
int 40.55944 1.72097 0.51158 0.01060 
F CONTROLS si -2.00608 1.17577 0.01194 0.00768 
int 56.78660 1.75842 0.43346 0.01150 
(S.E.=standard error, M=male, F=female f 
colo=colonized, sl=slope, int=intercept) 
The slopes and intercepts of the lines generated 
by regression analysis of FEV1 and RV/TLC data during 
the time period from -36 to -12 months and 0 to 24 
months are shown in table 2. They show no significant 
change in either parameter in colonized subjects, and a 
significantly more negative RV/TLC slope in controls 
with no difference in FEVl. When considered separ¬ 
ately, the males demonstrated a significant decrease 
in FEVl slope and increase in RV/TLC slope from the 
earlier time period to the later, but no change in the 
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two intercepts. The females showed no change in 
either parameter over time. 
In the earlier time period, neither the FEVl nor 
the RV/TLC parameters of the males were significantly 
different than those of the females, and no significant 
difference between the genders was seen in the later 
time period either. 
TABLE 2 
Regression analysis of FEVl and RV/TLC data 
of 33 subjects and controls from 36 to 12 months prior 
and from _0 months to 24 months following PC acquisition 
FEVl BEFORE S.E. AFTER S.E. 
COLO s 1 -3.00273 3.28244 -5.61402 2.55768 
int 46.53508 6.70651 45.41759 2.92495 
CONTROLS s 1 -4.95776 3.43811 -0.56106 2.91835 
int 53.33592 6.75844 55.96849 3.40726 
M COLO si 0.28578 4.05360 -7.94644 3.37762 
int 54.31509 8.30525 51.28824 4.03503 
M CONTROLS si -5.77907 5.01846 -0.51430 3.86950 
int 53.86584 9 . 72063 56.60343 4.44639 
F COLO s 1 -6.50609 5.34596 -3.83199 3.84390 
int 38.07909 10.88395 39.84930 4.16326 
F CONTROLS si -4.43410 4.56430 -0.42977 4.51520 
int 51.79176 9.13313 54.98022 5.38933 
RV/TLC 
COLO s 1 0.01686 0.01758 0.03826 0.01803 
int 0.48773 0.03600 0.47479 0.02054 
CONTROLS s 1 0.04535 0.02147 -0.00860 0.02099 
int 0.48993 0.04217 0.43678 0.03678 
M COLO s 1 0.01885 0.02406 0.07390 0.02273 
int 0.47935 0.04918 0.42023 0.02714 
M CONTROLS si 0.04443 0.03133 -0.01867 0.02843 
int 0.48039 0.06057 0.43245 0.03039 
F COLO s 1 0.01456 0.02585 -0.00541 0.02848 
int 0.49880 0.05311 0.53664 0.03036 
F CONTROLS si 0.04878 0.02880 -0.00268 0.03174 
int 0.50628 0.05762 0.44661 0.03751 
(Before=3 6 -12 months prior to PC acquisition, After=0-24 
months after PC acquisition, S.E. =standard error, 
Colo=coIonized by PC , M=male, F =female, sl=slope, int=intercept 
-51- 

T-test analysis of the individual regression 
parameters of each subject and control over the entire 
5 year time period revealed a significant difference 
in the mean FEV1 intercept between subjects and 
controls (p=.020), but no significant difference in 
the average slope between the two groups. Although 
the RV/TLC intercept was higher in subjects than 
controls, the difference was not quite statistically 
significant (p=.051). 
Multivariate analysis of variance confirmed that 
there was no significant association between FEVl or 
RV/TLC slope or intercept and sex, and that subjects' 
FEVl intercept was significantly lower than that of 
their controls (p=.024). The subjects' RV/TLC 
intercept was higher than that of the controls, but 
the difference was not statistically significant 
(p=. 05 3 ) . 
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DISCUSSION 5 . 
Colonization of CF patients with PC has become a 
common problem in the last decade, yet its impli¬ 
cations have not been clearly identified. This study 
attempts to define the effect of colonization by PC on 
the mortality and pulmonary function of patients with 
CF. Colonized patients who survived longer than one 
year following acquisition of PC were compared to 
those who died within a year, and differences between 
these groups prior to colonization which could predict 
clinical outcome were studied. In addition, differ¬ 
ences between the survivors and age and sex matched 
controls with respect to pulmonary function several 
years before and after acquisition of PC were sought. 
The mortality in the first year of colonization 
with PC is significantly increased over sex and age- 
matched controls who were not colonized. No differ¬ 
ence in mortality was seen in the second year, sugges¬ 
ting that patients colonized with PC who survive the 
first year stabilize and do not sustain increased mor¬ 
tality. These findings support, in part, the three 
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clinical courses of PC colonized CF patients proposed 
by Isles et al. (40). Their first group, which 
followed a fulminant and quickly fatal course, 
corresponds to those patients in this study who died 
in the first year, while their other two groups, who 
asymptomatically harbored the organism or progressive¬ 
ly deteriorated over a protracted period, correspond 
to the group in this study who survived the first 
year. No attempt was made in this study to distin¬ 
guish between these last two groups. 
Patients who did not survive at least one year 
after colonization with PC represent the worrisome 
clinical problem posed by this organism. In this 
study, mortality was the only measure of clinical 
outcome in these patients; they were excluded from 
regression analysis used to define the rate of decline 
in pulmonary function of the patients who survived 
longer because their data spanned such a short period 
of time that it made that analysis difficult to inter¬ 
pret . 
The quickly deteriorating group in this study was 
found in retrospect to differ from the others 
even before acquisition of PC. One year prior to 
colonization the mean percent of predicted FEV1 of 
those destined to survive more than one year following 
PC acquisition was significantly higher than that of 
-54- 

the others, and their mean RV/TLC was significantly 
lower, suggesting that poor pulmonary function prior 
to PC colonization predisposes to poor outcome. This 
may also support the hypothesis that PC does not 
change the downhill course of disease in these 
patients who were clearly in poor clinical condition 
prior to acquiring the organism. 
The average age that PC was acquired did not 
differ between those patients who survived one year 
and those who did not. In this study, however, the 
acquisition dates ranged from 1978 to 1984, and ages 
of PC acquisition have been changing with time, 
(14,87,91,92), possibly confounding these findings. It 
would be best to study the effect of age of acquisi¬ 
tion of PC on clinical course in patients who became 
colonized by the organism in a short time span, a 
design that was not possible with the data collected 
here. 
In the literature, other predictors of poor out¬ 
come have been noted. Isles et al. found that the 
presence of fever and leukocytosis in female CF 
patients at the time of hospitalization for a pulmo¬ 
nary exacerbation due to PC correlated well with poor 
outcome, but did not identify characteristics present 
prior to colonization which predicted poor outcome 
-55- 

(40). Some studies have addressed the question of 
increased risk of colonization (6,10,14,37,72,87, 
91,92) but not increased risk of poor outcome once a 
patient is colonized; others compare the clinical 
courses of colonized patients to those who are not 
colonized (10,87,91), rather than those of colonized 
patients who follow different courses. 
It would be useful to study other clinical 
characteristics of CF patients with PC in the patients 
who survived a year and those who did not. Differen¬ 
ces in overall clinical status, immune status, pre¬ 
vious therapeutic regimens, and nutritional status are 
some of the many parameters not addressed by this 
study which may be useful in predicting clinical out¬ 
come . 
The hypothesis that females colonized with PC 
have a poorer prognosis than males was tested and 
rejected. Thomassen et al. proposed that females had a 
more rapid decline in clinical status in the year 
following PC acquisition than did males, but did not 
address their relative mortality (91). While the 
present study did not examine the rate of decline of 
pulmonary function over the first year after coloniza¬ 
tion in all men compared to all women, it would be 
expected that if a more rapid decline occurred in 
females, increased mortality would accompany it. No 
-56- 

such difference was seen in the first or second years 
following colonization, suggesting that no difference 
in prognosis exists, or that small sample size made 
determination of such a difference impossible. 
The second group of subjects, those who survived 
more than one year, were studied to determine whether 
their pulmonary function differed markedly from con¬ 
trols who were not colonized with PC, despite their 
comparable mortality. Before regression analysis was 
done, figures 1 through 6 were plotted to get a 
general idea of the differences in data between sub¬ 
jects and controls. The highest FEV1 and lowest 
RV/TLC for each two month period was chosen to try to 
delete some of the variation within each patient's 
data due to poor effort or other confounding influen¬ 
ces. A great deal of variation remains, as evidenced 
by these graphs. Ideally, each point on these plots 
should represent the mean FEVl or RV/TLC of the same 
number of patients, but in this study not all patients 
had tests at the same intervals, so the number of 
patients represented by each point is variable. 
The regression analysis of these graphs showed 
poorer FEVl and RV/TLC and more marked decline in 
pulmonary function in colonized subjects than con¬ 
trols, and significant differences in FEVl and RV/TLC 
intercepts but not slopes between males and females. 
-57- 

The data used included the best FEV1 and RV/TLC values 
for each one month period, so as to include more 
points than the every two month values plotted in the 
graphs. The slopes and intercepts generated, however, 
included different numbers of data points for each 
patient, depending on the number of tests he/she had 
in the five years under study. 
In order to overcome this bias, regression analy¬ 
sis was performed on the data of each individual 
patient, and the slopes and intercepts generated were 
then analyzed to identify differences between colo¬ 
nized subjects and controls, and differences between 
males and females. The results of this analysis were 
somewhat different, showing no difference in slope for 
either the FEVl or RV/TLC data between subjects and 
controls, and a statistically significant difference 
only in the intercept of the FEVl data, not in that of 
the RV/TLC, although it was very close to significant. 
No difference between males and females were noted 
either. 
These findings support those of Corey et al., 
who found significantly lower absolute values of 
several pulmonary function parameters but comparable 
rates of change in pulmonary function in patients with 
PC as compared to those without the organism (14). 
While the above data gives an indication of the 
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clinical courses of colonized subjects and their con¬ 
trols over five years, it does not distinguish between 
their courses before and after acquisition of PC. In 
this study, there were not enough patients with suf¬ 
ficient data to do separate linear regression before 
and after PC acquisition on each individual and then 
compare them as above. Therefore, linear regression 
was done on data from all patients before and after 
colonization and is biased toward those with more 
tests. 
Overall there was no significant change in pulmo¬ 
nary function in patients following colonization with 
PC. A change was seen, however, in the rates of 
change of FEV1 and RV/TLC of male patients when con¬ 
sidered separately. This suggests that male survivors 
may actually have a worse course when colonized by PC 
than females, although the slopes were not 
significantly different from those of the females in 
either time period. As can be seen in table 2, how¬ 
ever, with the small number of data points there is a 
large standard error, which may account for the lack 





Patients with cystic fibrosis who became colo¬ 
nized with Pseudomonas cepacia were more likely to die 
in the year following acquisition of the organism than 
were age and sex-matched controls without PC. Those 
who did not die in the first year were not more likely 
than controls to die in the second year following 
colonization. No difference in mortality between 
males and females was observed. 
Those patients colonized with PC who died in the 
first year had lower mean FEV1 and higher mean RV/TLC 
values one year prior to acquisition of the organism 
than colonized patients who survived at least one year. 
Mean age of acquisition of PC was not useful in 
predicting whether death would ensue in the first 
year. 
Those patients who survived at least one year 
following PC colonization had significantly lower 
FEVl values than age and sex-matched controls without 
PC over the five year period from three years prior to 
colonization to two years post-colonization, but had 
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a comparable rate of decline in FEV1. Their RV/TLC 
values and rates of increase were not significantly 
different from those of controls. 
There were no significant differences in either 
the absolute values of FEVl and RV/TLC or in the rates 
of change of these parameters following acquisition of 
PC in patients who survived at least one year. When 
considered separately, males demonstrated a signifi¬ 
cant change for the worse in the slopes of their FEVl 
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